In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on BioCardia (BCDA – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $0.91.
According to TipRanks, Pantginis is an analyst with an average return of -5.6% and a 33.40% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Celldex, Panbela Therapeutics, and Onconova Therapeutics.
Currently, the analyst consensus on BioCardia is a Moderate Buy with an average price target of $9.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.92 and a one-year low of $0.85. Currently, BioCardia has an average volume of 105.6K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Read More on BCDA:
- BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
- BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
- BioCardia downgraded to Neutral from Buy at Alliance Global Partners
- Biotech Alert: Searches spiking for these stocks today
- BioCardia shares ‘oversold’ on news of trial pause, says H.C. Wainwright
